Press Releases ImmunoPrecise Antibodies Ltd.

Equities

IPA

CA45257F2008

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-31 pm EDT			5-day change	1st Jan Change
1.109 ^USD	+0.85%		-0.05%	-35.12%

Apr. 22	ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform	CI
Apr. 12	ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications	Mar. 28	BU
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments	Mar. 20	BU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024	Mar. 15	AQ
ImmunoPrecise Antibodies : Q3 2024 Earnings Presentation	Mar. 14	PU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*	Mar. 14	BU
IMMUNOPRECISE ANTIBODIES : MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2024 - Form 6-K	Mar. 14	PU
ImmunoPrecise Antibodies : Q3 2024 Earnings Transcript	Mar. 13	PU
IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology	Mar. 08	AQ
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology	Mar. 07	BU
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024	Mar. 04	BU
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024	Dec. 15	AQ
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*	Dec. 14	BU
IPA Announces Closing of $1.265 Million Public Offering of Common Shares	Dec. 11	AQ
IPA Announces Closing of $1.265 Million Public Offering of Common Shares	Dec. 08	BU
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares	Dec. 06	BU
IPA Announces Proposed Public Offering of Common Shares	Dec. 05	BU
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call	Nov. 27	BU
ImmunoPrecise Antibodies : Report of Voting Results Submitted Pursuant to - Form 6-K	Nov. 16	PU
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research	Nov. 13	BU
ImmunoPrecise Antibodies : Q1 2024 Earnings Presentation	23-10-29	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ImmunoPrecise Antibodies Ltd.

Equities

IPA

CA45257F2008

Press Releases

Filters